↓ Skip to main content

The Effects of Normal as Compared with Low Hematocrit Values in Patients with Cardiac Disease Who Are Receiving Hemodialysis and Epoetin

Overview of attention for article published in New England Journal of Medicine, August 1998
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

blogs
9 blogs
policy
4 policy sources
twitter
23 X users
patent
15 patents
f1000
1 research highlight platform

Citations

dimensions_citation
1864 Dimensions

Readers on

mendeley
505 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
The Effects of Normal as Compared with Low Hematocrit Values in Patients with Cardiac Disease Who Are Receiving Hemodialysis and Epoetin
Published in
New England Journal of Medicine, August 1998
DOI 10.1056/nejm199808273390903
Pubmed ID
Authors

Anatole Besarab, W. Kline Bolton, Jeffrey K. Browne, Joan C. Egrie, Allen R. Nissenson, Douglas M. Okamoto, Steve J. Schwab, David A. Goodkin

Abstract

In patients with end-stage renal disease, anemia develops as a result of erythropoietin deficiency, and recombinant human erythropoietin (epoetin) is prescribed to correct the anemia partially. We examined the risks and benefits of normalizing the hematocrit in patients with cardiac disease who were undergoing hemodialysis. We studied 1233 patients with clinical evidence of congestive heart failure or ischemic heart disease who were undergoing hemodialysis: 618 patients were assigned to receive increasing doses of epoetin to achieve and maintain a hematocrit of 42 percent, and 615 were assigned to receive doses of epoetin sufficient to maintain a hematocrit of 30 percent throughout the study. The median duration of treatment was 14 months. The primary end point was the length of time to death or a first nonfatal myocardial infarction. After 29 months, there were 183 deaths and 19 first nonfatal myocardial infarctions among the patients in the normal-hematocrit group and 150 deaths and 14 nonfatal myocardial infarctions among those in the low-hematocrit group (risk ratio for the normal-hematocrit group as compared with the low-hematocrit group, 1.3; 95 percent confidence interval, 0.9 to 1.9). Although the difference in event-free survival between the two groups did not reach the prespecified statistical stopping boundary, the study was halted. The causes of death in the two groups were similar. The mortality rates decreased with increasing hematocrit values in both groups. The patients in the normal-hematocrit group had a decline in the adequacy of dialysis and received intravenous iron dextran more often than those in the low-hematocrit group. In patients with clinically evident congestive heart failure or ischemic heart disease who are receiving hemodialysis, administration of epoetin to raise their hematocrit to 42 percent is not recommended.

X Demographics

X Demographics

The data shown below were collected from the profiles of 23 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 505 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Brazil 5 <1%
United States 4 <1%
Hungary 1 <1%
Australia 1 <1%
Korea, Republic of 1 <1%
Spain 1 <1%
United Kingdom 1 <1%
Unknown 491 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 73 14%
Student > Bachelor 54 11%
Other 53 10%
Student > Ph. D. Student 53 10%
Student > Postgraduate 43 9%
Other 140 28%
Unknown 89 18%
Readers by discipline Count As %
Medicine and Dentistry 256 51%
Agricultural and Biological Sciences 34 7%
Biochemistry, Genetics and Molecular Biology 28 6%
Pharmacology, Toxicology and Pharmaceutical Science 27 5%
Nursing and Health Professions 11 2%
Other 49 10%
Unknown 100 20%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 90. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 August 2023.
All research outputs
#468,207
of 25,353,525 outputs
Outputs from New England Journal of Medicine
#6,388
of 32,427 outputs
Outputs of similar age
#152
of 32,391 outputs
Outputs of similar age from New England Journal of Medicine
#6
of 121 outputs
Altmetric has tracked 25,353,525 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 32,427 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 121.8. This one has done well, scoring higher than 80% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 32,391 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 121 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.